Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. | Bruker ...

Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

In order to focus its resources on the phase 1 program, dubbed TIDAL-01, the company has today announced a reduction in staff ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...

The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data ...

Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...

Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing | Ono ...